Showing results (381-390 of 422) with videos related to

Sort By:
Pageof 43
Multiple Sclerosis and Related Disorders|February 15, 2022
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorderRomain Marignier, Sean J Pittock, Friedemann Paul, et al.
Annals of Clinical and Translational Neurology|September 10, 2021
A meta-analysis comparing first-line immunosuppressants in neuromyelitis opticaJonathan Giovannelli, Jonathan Ciron, Mikael Cohen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 4, 2021
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSDBruce Ac Cree, Jeffrey L Bennett, Ho Jin Kim, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 2, 2020
Recurrence of clinical events at the same anatomical location in patients with MOG antibody-associated diseaseJae-Won Hyun, Young Nam Kwon, Hye Lim Lee, et al.
Multiple Sclerosis and Related Disorders|September 9, 2023
Serum neurofilament and glial fibrillary acidic protein in idiopathic and seropositive transverse myelitisHye Lim Lee, Jin Myoung Seok, Yeon Hak Chung, et al.
The Lancet. Neurology|January 27, 2023
Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteriaBrenda Banwell, Jeffrey L Bennett, Romain Marignier, et al.
Journal of Clinical Neurology (Seoul, Korea)|November 11, 2022
Safety and Temporal Pattern of the Lymphocyte Count During Fingolimod Therapy in Patients With Multiple Sclerosis: Real-World Korean ExperienceSo-Young Huh, Su-Hyun Kim, Ki Hoon Kim, et al.
JAMA Neurology|December 23, 2024
Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG-Positive Neuromyelitis Optica Spectrum DisorderSu-Hyun Kim, Ana Beatriz Ayroza Galvão Ribeiro Gomes, Patrick Schindler, et al.
Lancet (London, England)|September 10, 2019
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialBruce A C Cree, Jeffrey L Bennett, Ho Jin Kim, et al.
Frontiers in Immunology|April 5, 2024
Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorderEun Bin Cho, Ju-Hong Min, Patrick Waters, et al.
Pageof 43